Nasdaq Stocks

Whether it is time to buy airline stocks could depend on whether the U.S. avoids a recession or not.

Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of Valley National Bancorp (Symbol: VLY) were yielding above the 5% mark based on its quarterly dividend (annualized to $0.44), with the stock changing hands as low as $8.77 on the

Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of W.P. Carey Inc (Symbol: WPC) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.152), with the stock changing hands as low as $82.69 on the day. Di

Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of Nordstrom, Inc. (Symbol: JWN) were yielding above the 5% mark based on its quarterly dividend (annualized to $1.48), with the stock changing hands as low as $29.54 on the day. Di

Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of FedEx Corp (Symbol: FDX) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.6), with the stock changing hands as low as $128.75 on the day. Dividen

The Dow started the day down around 700 points, but seemed content to hold around there through the morning. It wasn’t until early afternoon that investors decided that the stock market needed to fall even more.

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on February 28, Union Pacific Corp's CHIEF OPERATING OFFICER, Vincenzo J. Vena, invested $499,863.81 into 3,206 shares of UNP, for a co

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.

Bank of America analyst upgrades Amgen, downgrades Moderna.

The Dow Jones Industrial Average is falling 814 points, or 3%. The S&P 500 is losing 2.8%, and the Nasdaq Composite is slipping 2.3%. 

The market expects Senseonics Holdings (SENS) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2019. This widely-known consensus outlook is important in assessing the company's earnings picture, but a power

Rimini Street, Inc. (RMNI) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual re

Reeds (REED) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare t

AVEO Pharmaceuticals (AVEO) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual re